Physician profile
Laura Crecelius
NPI 1861470627
$1,897.11
in general payments reported to CMS, 2019-2025
22 companies · $271 in 2025
The $271 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $262 · 2021: $264 · 2022: $316 · 2023: $299 · 2024: $322 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $891.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $258.21 | 2019-2022 | |
| Novo Nordisk INC | $245.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $179.36 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $134.06 | 2022-2024 | |
| Astellas Pharma US INC | $131.54 | 2024-2025 | Veozah |
| Lilly USA, LLC | $123.67 | 2019-2024 | Zepbound |
| Abbvie INC. | $118.67 | 2021-2025 | Ubrelvy |
| Merck Sharp & Dohme LLC | $108.26 | 2019-2024 | Gardasil 9, Gardasil, Vaqta |
| Biohaven Pharmaceutical Holding Company LTD. | $105.23 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.72 | 2020-2023 | Xifaxan |
| Pfizer INC. | $83.43 | 2023-2025 | |
| Exact Sciences Corporation | $45.64 | 2023-2024 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $42.33 | 2023 | Coolseal Generator, Myosure Tissue Removal Device |
| Phathom Pharmaceuticals, INC. | $42.04 | 2024 | Voquezna |
| Mylan Specialty L.P. | $36.24 | 2022-2023 | Yupelri |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $34.33 | 2020-2022 | |
| Radius Health, INC. | $29.89 | 2025 | Tymlos |
| Biohaven Pharmaceuticals, INC. | $27.74 | 2021 | |
| Mckesson Medical-Surgical, INC. | $20.21 | 2025 | |
| Amgen INC. | $13.98 | 2020 | |
| Sumitomo Pharma America, INC. | $13.34 | 2024 | Myfembree |
| Glaxosmithkline, LLC. | $11.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Crecelius listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.